[go: up one dir, main page]

MX2020011293A - Conjugados del peptido de fusion peptido similar al glucagon 1 (glp-1) acoplado al peptido tirosina tirosina ciclico y usos de estos. - Google Patents

Conjugados del peptido de fusion peptido similar al glucagon 1 (glp-1) acoplado al peptido tirosina tirosina ciclico y usos de estos.

Info

Publication number
MX2020011293A
MX2020011293A MX2020011293A MX2020011293A MX2020011293A MX 2020011293 A MX2020011293 A MX 2020011293A MX 2020011293 A MX2020011293 A MX 2020011293A MX 2020011293 A MX2020011293 A MX 2020011293A MX 2020011293 A MX2020011293 A MX 2020011293A
Authority
MX
Mexico
Prior art keywords
peptide
tyrosine
conjugates
glp
coupled
Prior art date
Application number
MX2020011293A
Other languages
English (en)
Inventor
Suzanne Edavettal
Wilson Edwards
Ellen Chi
Rui Zhang
Yue - Mei Zhang
Raul Camacho
Martin A Case
Lisa Norquay
Mark J Wall
Songmao Zheng
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020011293A publication Critical patent/MX2020011293A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención comprende conjugados que comprenden un péptido de fusión péptido similar al glucagón 1 (GLP-1) acoplado a un péptido PYY cíclico; la invención también se relaciona con composiciones farmacéuticas y con métodos para usarlas; los conjugados novedosos son útiles para prevenir, tratar o corregir enfermedades y trastornos descritos en la presente descripción.
MX2020011293A 2018-04-25 2019-04-24 Conjugados del peptido de fusion peptido similar al glucagon 1 (glp-1) acoplado al peptido tirosina tirosina ciclico y usos de estos. MX2020011293A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662313P 2018-04-25 2018-04-25
US2018029284 2018-04-25
PCT/IB2019/053384 WO2019207505A1 (en) 2018-04-25 2019-04-24 Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2020011293A true MX2020011293A (es) 2020-11-13

Family

ID=66676857

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011293A MX2020011293A (es) 2018-04-25 2019-04-24 Conjugados del peptido de fusion peptido similar al glucagon 1 (glp-1) acoplado al peptido tirosina tirosina ciclico y usos de estos.

Country Status (26)

Country Link
EP (2) EP3784692B1 (es)
JP (2) JP7676148B2 (es)
KR (2) KR20250142942A (es)
CN (2) CN119708256A (es)
AU (2) AU2019259790B2 (es)
BR (1) BR112020021562A2 (es)
CA (1) CA3096792A1 (es)
CL (1) CL2020002718A1 (es)
CO (1) CO2020013221A2 (es)
CR (1) CR20200487A (es)
DO (1) DOP2020000192A (es)
EC (1) ECSP20067968A (es)
ES (1) ES3049134T3 (es)
IL (2) IL278197B2 (es)
JO (1) JOP20200265A1 (es)
MA (1) MA52361A (es)
MX (1) MX2020011293A (es)
MY (1) MY207588A (es)
NI (1) NI202000071A (es)
PE (1) PE20211457A1 (es)
PH (1) PH12020551659A1 (es)
SA (1) SA520420401B1 (es)
SG (1) SG11202009844SA (es)
TW (1) TWI847981B (es)
UY (1) UY38200A (es)
WO (1) WO2019207505A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
CA3163507A1 (en) * 2019-12-04 2021-06-10 The Scripps Research Institute Peptide conjugates and methods of use
KR20230045088A (ko) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제
CN119638849A (zh) * 2021-10-18 2025-03-18 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
CN116478298A (zh) * 2021-12-31 2023-07-25 广东东阳光药业有限公司 Glp-1和gdf15的融合蛋白及其用途
CN119677527A (zh) 2022-08-18 2025-03-21 勃林格殷格翰国际有限公司 包含长效glp-1/胰高血糖素及npy2受体激动剂的组合疗法
CN117327200B (zh) * 2023-11-28 2024-02-09 西宝生物科技（上海）股份有限公司 一种调控糖脂代谢和抗衰老的双功能重组蛋白gik及其制备方法
WO2025247862A1 (en) * 2024-05-27 2025-12-04 Numaferm Gmbh Methods for the c-terminal modification of (poly)peptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422806A3 (en) 2004-02-11 2012-06-13 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
MXPA06010347A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
RU2428431C2 (ru) 2004-12-02 2011-09-10 Домантис Лимитед Слитые конструкции лекарственного средства и конъюгаты
WO2007018619A2 (en) * 2005-07-29 2007-02-15 Amprotein Corporation Chimeric therapeutic agents
EA014647B1 (ru) 2005-08-11 2010-12-30 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
CA2660835A1 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
MX2012003939A (es) 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
BR112018008681A2 (pt) * 2015-10-28 2018-10-30 Tufts Medical Center novos polipeptídeos com estabilidade proteolítica melhorada, e métodos para preparar e usar os mesmos
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y

Also Published As

Publication number Publication date
UY38200A (es) 2019-10-31
JP2025118735A (ja) 2025-08-13
AU2023274117B2 (en) 2025-04-10
JP2021522258A (ja) 2021-08-30
EP3784692B1 (en) 2025-08-27
KR102865076B1 (ko) 2025-09-25
IL278197B1 (en) 2025-03-01
DOP2020000192A (es) 2021-04-30
AU2023274117A1 (en) 2023-12-21
KR20210005674A (ko) 2021-01-14
ES3049134T3 (en) 2025-12-15
JP7676148B2 (ja) 2025-05-14
CN112004822A (zh) 2020-11-27
MA52361A (fr) 2021-03-03
CL2020002718A1 (es) 2021-01-29
NI202000071A (es) 2021-01-21
AU2019259790A1 (en) 2020-10-22
WO2019207505A1 (en) 2019-10-31
SA520420401B1 (ar) 2023-01-26
CO2020013221A2 (es) 2020-11-10
JOP20200265A1 (ar) 2020-10-21
PH12020551659A1 (en) 2021-07-26
EP3784692C0 (en) 2025-08-27
EP4640701A2 (en) 2025-10-29
MY207588A (en) 2025-03-05
TWI847981B (zh) 2024-07-11
EP4640701A3 (en) 2025-12-17
KR20250142942A (ko) 2025-09-30
IL278197A (en) 2020-11-30
IL278197B2 (en) 2025-07-01
EP3784692A1 (en) 2021-03-03
SG11202009844SA (en) 2020-11-27
CR20200487A (es) 2021-03-11
TW202014433A (zh) 2020-04-16
PE20211457A1 (es) 2021-08-05
CN119708256A (zh) 2025-03-28
CA3096792A1 (en) 2019-10-31
CN112004822B (zh) 2025-01-14
BR112020021562A2 (pt) 2021-03-02
AU2019259790B2 (en) 2023-08-31
IL319050A (en) 2025-04-01
ECSP20067968A (es) 2020-11-30

Similar Documents

Publication Publication Date Title
MX2020011293A (es) Conjugados del peptido de fusion peptido similar al glucagon 1 (glp-1) acoplado al peptido tirosina tirosina ciclico y usos de estos.
PH12019500749A1 (en) Antibody-coupled cyclic peptide tyrosine compounds as modulators of neuropeptide y receptors
CO2019006912A2 (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
CY1123623T1 (el) Θεραπεια νευρολογικων νοσων
MX388822B (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2022007439A (es) Antagonistas de piperidina del receptor de melanocortina subtipo 2 (mc2r) sustituidos con gem y usos de los mismos.
MY200962A (en) Amide Derivatives As Nav1.7 And Nav1.8 Blockers
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
AR101871A1 (es) Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
MX2021007425A (es) Derivados heterociclicos como bloqueadores de nav1.7 y nav1.8.
MX9302475A (es) Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.
MX2024006771A (es) Forma cristalina de n-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihid roquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfo namida.
NO20080552L (no) GLP-1 farmasoytiske sammensetninger
EA202092547A1 (ru) Связанные со слитым пептидом, содержащим глюкагонподобный пептид 1 (glp-1), циклические пептидные тирозинтирозиновые конъюгаты и их применение
CL2021003497A1 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1
MX2022006743A (es) Formulaciones liquidas estables de peptido 1 similar al glucagon o analogos del mismo.
UA122320U (uk) Протизапальний засіб для лікування захворювань суглобів і хребта "диклофенак-віола"
EA202092756A1 (ru) Конденсированные бициклические соединения для применения в качестве ингибиторов убиквитин-специфической пептидазы 30
CL2018002690A1 (es) Variantes del anticuerpo humanizado ban2401 que se une específicamente a protofibrillas con una vida media serica aumentada composiciones farmacéuticas y usos en el tratamiento del alzheimer y otras enfermedades neurodegenerativas (divisional de la solicitud n° 53-2017).